

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

BALANCE SHEET AS AT 31st March, 2017

	Particulars	Note No	AS AT 31.03.2016	AS AT 31.03.2017
I	Trust Funds / Corpus			
	Contribution of CPSEs	1	7,500,000.00	7,500,000.00
	Reserves & Surplus			
	Grants - in - AID	2	323,415,445.36	665,621,217.85
	Current Liabilities			
	Trade Payables	3	76,035,480.00	224,518,756.00
	Others Liabilities	4	21,281,629.00	38,624,526.71
	Total		428,232,554.36	936,264,500.56
II	ASSETS			
	Non-Current Assets			
	<i>Fixed assets</i>	5		
	(i) Tangible assets		2,591,032.00	4,024,215.00
	(ii) Intangible assets		239,502.00	722,721.00
	Current Assets			
	Inventories	6	140,873,093.59	485,970,246.86
	Trade receivables	7	51,546,751.00	123,559,114.29
	Cash and cash equivalents	8	214,570,698.42	305,430,327.41
	Short-term loans and advances	9	8,059,736.00	4,786,450.00
	Other Current Assets	10	10,351,741.35	11,771,426.00
	Total		428,232,554.36	936,264,500.56
	Significant Accounting Policies & Other Notes	18		
III	NOTES TO THE FINANCIAL STATEMENTS	1 - 18		

As per our Report of even date
For RSMA & Company
Chartered Accountants
(Firm Registration No.: 028685N)

CA Ravinder Singh

Partner

Membership No-095973

Place: New Delhi

Date: 20 SEP 2017

For Bureau of Pharma Public Sector Undertakings of India


Director (A&F)

Nikunja Bihari Sarangi
Director (Admn. & Finance)
BUREAU OF PHARMA PSUs OF INDIA
(Set up Under the Department of Pharmaceuticals, Govt. of India)
IDPL Corporate Office, Old Delhi Gurgaon Road
Dundahera, Gurgaon-122016 (HR)


CEO & SECRETARY GENERAL

Biplab Chatterjee
Chief Executive Officer (CEO)
BUREAU OF PHARMA PSUs OF INDIA
(Set up Under the Department of Pharmaceuticals, Govt. of India)
IDPL Corporate Office, Old Delhi Gurgaon Road
Dundahera, Gurgaon-122016 (HR)

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH 2017**

	Particulars	Note No	YEAR ENDED 31.03.2016	YEAR ENDED 31.03.2017
I	Revenue from operations	11	93,510,960.00	251,233,652.00
II	Other Income	12	17,028,369.91	20,905,186.65
III	Total Revenue (I+II)		110,539,329.91	272,138,838.65
IV	<u>Expenses:</u>			
	Costs of Goods Purchased	13	174,408,221.00	506,653,396.00
	Change in Inventories (Finished Goods)	14	(92,245,913.59)	(345,097,152.72)
	Employee Benefit Expenses	15	12,528,967.00	25,649,957.00
	Finance costs	16	32,477.00	64,068.76
	Depreciation and amortization expense	5	818,967.00	1,507,403.00
	Other expenses	17	38,041,627.58	91,155,394.12
	Total Expenses		133,584,345.99	279,933,066.16
V	Profit /(Loss) before tax (III-IV)		(23,045,016.08)	(7,794,227.51)
VI	Profit /(Loss) before tax (III-IV)		(23,045,016.08)	(7,794,227.51)
VII	Significant Accounting Policies & other Notes	18		
VIII	NOTES FORMING PART OF THE FINANCIAL STATEMENTS	1 to 18		

As per our Report of even date
For RSMA & Company
Chartered Accountants
(Firm Registration No.: 028685N)


CA Ravinder Singh
Partner
Membership No-095973



For Bureau of Pharma Public Sector Undertakings of India


Director (A&F)

Nikunja Bihari Sarangi
Director (Admn. & Finance)
BUREAU OF PHARMA PSUs OF INDIA
(Set up Under the Department of Pharmaceuticals, Govt. of India)
IDPL Corporate Office, Old Delhi Gurgaon Road
Dundahera, Gurgaon-122016 (HR)


CEO & SECRETARY GENERAL

Biplab Chatterjee
Chief Executive Officer (CEO)
BUREAU OF PHARMA PSUs OF INDIA
(Set up Under the Department of Pharmaceuticals, Govt. of India)
IDPL Corporate Office, Old Delhi Gurgaon Road
Dundahera, Gurgaon-122016 (HR)

Date: 20 SEP 2017